We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

BECKMAN COULTER, INC.

Beckman Coulter develops, manufactures and markets laboratory systems, reagents, centrifugation, lab automation, elec... read more Featured Products: More products

Download Mobile App




Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

By LabMedica International staff writers
Posted on 16 Jul 2024

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes have occurred. More...

Historically, a definitive diagnosis of Alzheimer’s disease could only be confirmed through an autopsy. In the last two decades, advanced brain imaging techniques such as PET, CT, and MRI have been developed to aid in the diagnosis of Alzheimer’s disease more reliably; however, these methods are costly, expose patients to radiation, and are not accessible to everyone. In search of a more accessible and straightforward method to assess brain health, the focus has shifted towards biomarkers. The detection of biomarkers in blood is now seen as the future of Alzheimer’s disease diagnosis. Now, a new collaboration for the use of a proprietary antibody to detect a crucial biomarker for Alzheimer's through a blood test marks a significant step forward in diagnosing the disease.

Beckman Coulter Diagnostics (Brea, CA, USA) has signed a licensing agreement with ALZpath Inc. (Carlsbad, CA, USA) to use its top-tier ALZpath pTau217 antibody in a blood-based in vitro diagnostic (IVD) test on its DxI 9000 Immunoassay Analyzer. This proprietary ALZpath pTau217 antibody, employed in blood-based assays, has demonstrated high diagnostic accuracy, sensitivity, and reliability in identifying the presence and progression of Alzheimer's disease—information that is increasingly vital for clinicians and researchers as new treatment options become available.

Blood-based assays using the ALZpath pTau217 antibody offer diagnostic accuracy comparable to traditional methods like PET imaging and cerebral spinal fluid (CSF) testing, but they are more accessible and affordable, involving a simple, less invasive blood test that can be performed in various clinical settings. The DxI 9000 Immunoassay Analyzer, available worldwide, is Beckman Coulter's latest immunoassay platform. It features the unique Lumi-Phos PRO substrate, facilitating the development of clinically relevant, highly sensitive assays that meet the evolving demands of healthcare. The DxI 9000 combines this enhanced sensitivity with leading throughput, reliability, reproducibility, and quality in core laboratory operations, along with a comprehensive menu of tests.

"We recognize the critical need for more sensitive, precise, and scalable diagnostic testing for Alzheimer's disease," said Kathleen Orland, senior vice president, general manager, Chemistry, and Immunoassay for Beckman Coulter Diagnostics. "We selected ALZpath's pTau217 antibody following rigorous evaluation due to its high performance in detecting amyloid pathology and ability to integrate into our advanced DxI 9000 platform to support broad-based testing. We are excited about the combination of ALZpath and Beckman Coulter innovations coming together to develop a new fully automated, high throughput, blood-based Alzheimer's disease test for the millions of patients who suffer from dementia worldwide."

"Alzheimer's disease affects tens of millions of people worldwide, but many remain undiagnosed and are consequently unable to be identified for clinical trials or get access to emerging treatments," added Chad Holland, CEO and president at ALZpath. "Collaborating with Beckman Coulter to integrate our pTau217 antibody into a highly accurate blood-based test run on their DxI 9000 analyzers will significantly expand access to precise testing and early diagnosis for patients around the world."

Related Links:
Beckman Coulter Diagnostics 
ALZpath Inc.


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
C-Reactive Protein Rapid Test
Afinion CRP
New
Whole Blood Control
Lyphochek Whole Blood Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: Schematic overview of the deep learning-based circulating exosome analysis for lung cancer detection (Photo courtesy of Chuan Xu, Cheng Jiang)

Liquid Biopsy Approach to Transform Diagnosis, Monitoring and Treatment of Lung Cancer

Lung cancer continues to be a major contributor to cancer-related deaths globally, with its biological complexity and diverse regulatory processes making diagnosis and treatment particularly difficult.... Read more

Pathology

view channel
Image: The Aiforia Breast Cancer Grading AI solution is CE-IVD marked (Photo courtesy of Aiforia Technologies)

Clinical AI Solution for Automatic Breast Cancer Grading Improves Diagnostic Accuracy

Labs that use traditional image analysis methods often suffer from bottlenecks and delays. By digitizing their pathology practices, labs can streamline their work, allowing them to take on larger caseloads... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.